Confrontation naming does not add incremental diagnostic utility in MCI and Alzheimer's disease

Julie A. Testa, Robert J. Ivnik, Bradley Boeve, Ronald C. Petersen, Shane V. Pankratz, David Knopman, Eric Tangalos, Glenn E. Smith

Research output: Contribution to journalArticlepeer-review

39 Scopus citations


As the incidence of dementia increases, there is a growing need to determine the diagnostic utility of specific neuropsychological tests in the early diagnosis of Alzheimer's disease (AD). In this study, the relative utility of Boston Naming Test (BNT) in the diagnosis of AD was examined and compared to the diagnostic utility of other neuropsychological measures commonly used in the evaluation of AD. Individuals with AD (n = 306), Mild Cognitive Impairment (MCI; n = 67), and cognitively normal subjects (n = 409) with at least 2 annual evaluations were included. Logistic regression analysis suggested that initial BNT impairment is associated with increased risk of subsequent AD diagnosis. However, this risk is significantly less than that imparted by measures of delayed recall impairments. A multivariate Cox proportional hazards regression analysis suggested that BNT impairment imparted no additional risk for subsequent AD diagnosis after delayed recall impairments were included in the model. Although BNT impairment occurred in all severity groups, it was ubiquitous only in moderate to severe dementia. Collectively these results suggest that although BNT impairments become more common as AD progresses, they are neither necessary for the diagnosis of AD nor particularly useful in identifying early AD.

Original languageEnglish (US)
Pages (from-to)504-512
Number of pages9
JournalJournal of the International Neuropsychological Society
Issue number4
StatePublished - Jul 2004


  • Alzheimer's disease
  • Boston naming test
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Psychology
  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Confrontation naming does not add incremental diagnostic utility in MCI and Alzheimer's disease'. Together they form a unique fingerprint.

Cite this